Lg Chem, Ltd

Korea Advanced Institute of Science and Technology

Jung Yun Choi

Chul Woong Kim

Donggyun Kang

Hye Ok Kang

Yeonju Lee

Sungwoon Heo

In Young Huh

Jae Hyung Kim

Younghyun Cho

Bum Soo Kim

Eungwon Kim

Suhyun Cho

Banseok Choi

Yong Mahn Han

Provided is a method for preparing a block copolymer including a step of subjecting a lactide monomer to ring-opening polymerization in the presence of a biosynthesized poly(3-hydroxypropionate) initiator to prepare a polylactide-poly(3-hydroxypropionate) block copolymer.

Method for preparing block copolymer

Provided is a biopolymer composition, a preparation method for the same, and a bioplastic using the same, the biopolymer composition comprising at least 83.5 weight % of a copolymer resin of lactic acid (LA) and 3-hydroxypropionate (3HP), an antioxidant, and a lubricant, and the composition having an elongation percentage of at least 90% but not greater than 500%.

Biopolymer composition, preparation method for same and bioplastic using same

The present invention relates to a novel 3-hydroxypropionate-lactate block copolymer [P(3HP-b-LA)], and a method for preparing same, and more specifically, provides a method for preparing a 3-hydroxypropionate-lactate block copolymer, and a 3-hydroxypropionate-lactate block copolymer produced thereby, the method comprising: a first culture step in which, by using recombinantimproved so as to be incapable of biosynthesizing lactic acid, P(3HP) is biosynthesized at the early stage of culturing by having glycerol as a carbon source and through 3-hydroxypropionate-generating genes and an enhanced PHA synthase; and a second culture step in which P(3HP) production is inhibited by using a carbon catabolic repression system for selectively introducing only glucose intowhen glycerol and glucose are supplied together as carbon sources, and in which polylactate is biosynthesized to an interrupted P(3HP) terminus by the enabling of the expression of a lactate synthase and a lactyl-CoA converting enzyme through an IPTG induction system.

Poly(3-hydroxypropionate-b-lactate) block copolymer using microorganisms

Provided is a method for preparing a block copolymer, the method comprising subjecting a lactide monomer to a ring-opening polymerization in the presence of a poly(3-hydroxypropionate) initiator to prepare a polylactide-poly(3-hydroxypropionate)block copolymer.

Process for preparation of block copolymer

Provided is a triblock copolymer comprising a poly(3-hydroxypropionate) block, and polylactide blocks bonded to both ends of the poly(3-hydroxypropionate) block. Also provided is a method for preparing a triblock copolymer by ring-opening polymerization of lactide monomers in the presence of a poly(3-hydroxypropionate) initiator having hydroxy groups at both ends.

Triblock copolymer and process for preparation thereof

Provided is a lactic acid-based block copolymer which is biodegradable while having excellent mechanical properties.

Block copolymer

Provided are a novel 3-hydroxypropionate-lactate block copolymer [P(3HP-b-LA)], and a method for preparing same, comprising: a) transforming a recombinant microorganism modified to be incapable of biosynthesizing lactic acid with a vector including a 3-hydroxypropionyl-CoA biosynthesis gene and a polyhydroxyalkanoate (PHA) synthetase gene, and a vector including a lactate biosynthesis gene and a gene of an enzyme that converts lactate to lactyl-CoA; (b) synthesizing poly(3-hydroxypropionate) (P(3HP)) by culturing the recombinant microorganism using a glycerol as a carbon source; and (c) inhibiting P(3HP) production by adding IPTG and glucose, and biosynthesizing polylactate (PLA) at the end of P(3HP) synthesized in step (b) by enabling the expression of a lactate biosynthesis enzyme and an enzyme that converts lactate to lactyl-CoA. Also provided is a recombinant microorganism produced in step a).

The present invention relates to a pharmaceutical composition for the prevention or treatment of CFC (cardiofaciocutaneous) syndrome comprising a TGF-&#x3b2; signaling pathway inhibitor or a BMP signaling pathway activator. The treatment of SB-431542 or BMP4 protein was confirmed to increase the ALP activity and bone mineral deposition in the osteoblasts originated from the induced pluripotent stem cells derived from CFC syndrome patients. Thus, the TGF-&#x3b2; signaling pathway inhibitor containing SB-431542 or the BMP signaling pathway activator containing BMP4 protein can be effectively used for the prevention or treatment of CFC syndrome.

Growing community of inventors

Daejeon, South Korea

Jung Yun Choi